| 8.46 0.29 (3.55%) | 05-13 14:48 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 9.98 |
1-year : | 11.66 |
| Resists | First : | 8.55 |
Second : | 9.98 |
| Pivot price | 7.74 |
|||
| Supports | First : | 7.22 |
Second : | 6.4 |
| MAs | MA(5) : | 8.07 |
MA(20) : | 7.61 |
| MA(100) : | 6.71 |
MA(250) : | 5.76 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 83.4 |
D(3) : | 76.1 |
| RSI | RSI(14): 69.8 |
|||
| 52-week | High : | 11 | Low : | 3.71 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ UNCY ] has closed below upper band by 4.9%. Bollinger Bands are 37.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 8.18 - 8.21 | 8.21 - 8.25 |
| Low: | 7.78 - 7.82 | 7.82 - 7.85 |
| Close: | 8.11 - 8.17 | 8.17 - 8.23 |
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
Tue, 12 May 2026
Unicycive Therapeutics stock (US90467V1098): Q1 2026 results and PDUFA update - AD HOC NEWS
Tue, 12 May 2026
Unicycive Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Tue, 12 May 2026
Unicycive (NASDAQ: UNCY) Q1 2026 loss deepens as warrant liability swings - Stock Titan
Tue, 12 May 2026
Unicycive Therapeutics Provides Update on FDA Review and Financial Results Ahead of OLC Launch Preparations - Quiver Quantitative
Tue, 12 May 2026
Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update - ChartMill
Tue, 12 May 2026
FDA June 29 decision looms on Unicycive kidney drug for dialysis patients - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 25 (M) |
| Shares Float | 23 (M) |
| Held by Insiders | 2.3 (%) |
| Held by Institutions | 32.2 (%) |
| Shares Short | 2,160 (K) |
| Shares Short P.Month | 1,720 (K) |
| EPS | -1.67 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.37 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -45.7 % |
| Return on Equity (ttm) | -141.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.17 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -31 (M) |
| Levered Free Cash Flow | -23 (M) |
| PE Ratio | -5.07 |
| PEG Ratio | 0 |
| Price to Book value | 6.17 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.83 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|